News Story: Full Text
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website


Restoration of Sensitivity in Chemo - Resistant Glioma Cells by Cold Atmospheric Plasma. [Full Text]


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

 This is the full text of the technical article on Cold Atmospheric Plasma.  See previous article for layman's version!



Website: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0064498

Posted on: 05/26/2013

Go to http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0064498 for the full text. This is the abstract:

 

PLoS One. 2013 May 21;8(5):e64498. Print 2013.

Restoration of Sensitivity in Chemo - Resistant Glioma Cells by Cold Atmospheric Plasma.

Köritzer J, Boxhammer V, Schäfer A, Shimizu T, Klämpfl TG, Li YF, Welz C, Schwenk-Zieger S, Morfill GE, Zimmermann JL, Schlegel J.

Max Planck Institute for Extraterrestrial Physics, Garching, Germany.

 

Abstract

Glioblastoma (GBM) is the most common and aggressive brain tumor in adults. Despite multimodal treatments including surgery, chemotherapy and radiotherapy the prognosis remains poor and relapse occurs regularly. The alkylating agent temozolomide (TMZ) has been shown to improve the overall survival in patients with malignant gliomas, especially in tumors with methylated promoter of the O6-methylguanine-DNA-methyltransferase (MGMT) gene. However, intrinsic and acquired resistance towards TMZ makes it crucial to find new therapeutic strategies aimed at improving the prognosis of patients suffering from malignant gliomas. Cold atmospheric plasma is a new auspicious candidate in cancer treatment. In the present study we demonstrate the anti-cancer properties of different dosages of cold atmospheric plasma (CAP) both in TMZ-sensitive and TMZ-resistant cells by proliferation assay, immunoblotting, cell cycle analysis, and clonogenicity assay. Importantly, CAP treatment restored the responsiveness of resistant glioma cells towards TMZ therapy. Concomitant treatment with CAP and TMZ led to inhibition of cell growth and cell cycle arrest, thus CAP might be a promising candidate for combination therapy especially for patients suffering from GBMs showing an unfavorable MGMT status and TMZ resistance.

 

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740